Table 1 : DUB's implicated in various cancers and cancer related pathways.

A. Cancer associated DUBs (CAD) - DUBs with altered expression or inherently
mutated in cancers

CYLD Cylindromatosis, Brooke Spiegler Syndrome, Trichoepithelioma,  hepatocellular carcinoma, colon cancer, kidney cancer, uterine cervix carcinoma, and malignant melanoma [12,14,40]
USP1 Fanconi Anemia and Gastric cancer [41]
USP2 Breast tumor, Glioma, oral squamous cell carcinoma, Ovarian Carcinoma and prostrate carcinomas [12,14,42,43]
USP4 Small-cell lung carcinoma [12]
USP6 Benign bone tumor and Neoplastic aneurismal bone cysts [12,44]
USP7 Multiple myeloma, prostrate cancer, non-small cell lung carcinomas, renal carcinoma and colon cancer [12,14, 45]
USP9X Breast cancer, pancreatic-ductal adenocarcinoma, cervical carcinoma [46,47,48]
USP10 Breast cancer, glioblastoma multiforme, Multiple melanoma [12,48,49]
USP11 Malignant melanoma [41]
USP14 Cholangiocarcinoma [50]
USP15 Paclitaxel resistant ovarian cancer and Glioblastoma [12]
USP17 Primary lung, colon, esophagus and cervix tumor [12]
USP20 Von Hippel-Lindau cancer syndrome [12]
USP22 Papillary thyroid carcinoma,Non-small cell lung carcinoma, Oral squamous cell carcinoma, human esophageal squamous cell carcinoma, Malignant melanoma and colorectal carcinomas, Gastric carcinoma, breast cancer [12,49,51-56]
USP25 Breast Cancer [48]
USP28 Lobular breast carcinoma and colon cancer [12,14]
USP32 Breast Cancer [57]
USP33 Von Hippel-Lindau cancer syndrome and
B cell-acute lymphoblastic leukemia
USP42 Acute Myeloid leukemia [59]
USP44 Human T-cell leukemia [60]
USP48 Malignant melanoma [41]
UCHL1 Meningiomas, Protrate cancer, non-small cell lung carcinomas and Breast cancer [12, 61,62]
UCHL5 Human esophageal squamous cell carcinoma [63]
BAP1 Breast cancer, pleural mesotheliomas, uveal melanomas, cutaneous melanoma and Non-small cell lung cancer [12,14,64]
A20 Lymphomas- including B cell lymphomas, Hodgkin lymphoma, mantle cell lymphoma, MALT lymphoma, marginal zone lymphoma [12,14]
JOSD1 Nonsmall cell lung carcinoma [41]
CSN5 Nonsmall cell lung carcinomas, Nasopharyngeal Carcinoma,  malignant melanoma [12,41]

B. Cancer related redundant pathway associated DUBs (CRRPAD)

Chromatin associated DUBs DUBs participating in Chromatin remodelling USP3, USP7, USP10, USP11, USP16, USP21, USP22, BAP1, BRCC36, MYSM1 and UCHL5 [12,14,65]
DNA Damage repair related DUBs USP1, USP3, USP7S, USP11, USP16, USP24, USP28, USP47, BRCC36, OTUB1 and POH1 [12,66-68]
DUBs manipulating the  Signalling pathways Innate immune response and Inflammatory pathways – JAK-STAT pathway JNK-p38-MAPK pathway; TLR pathway USP2, USP4, USP11, USP15, USP17, USP18, USP25, A20 and MCPIP1 [69-77]
NFκβ Signalling pathway USP2, USP4, USP6, USP7, USP11, USP15, USP21, A20, CYLD, MCPIP1, OTUD5, OTUD7B and Cezanne [12,70,78-82]
p53- and Cyclin dependent kinase Inhibitor (CKI) related pathways USP2, USP4, USP5, USP7, USP10, USP11, USP22, USP29, SP37, UCHL1 and OTUB1 [12,62,83-86]
PI3K-AKT related pathways-RTK dependent pathways, MTOR pathway, GSK3β pathway USP1, USP8, USP 9X, USP22 and UCHL1 [84,87-90]
TGF-β pathway USP4, USP9X,USP11,USP15,STAMBPL1and UCHL5                 [12,91]
Wnt pathway USP4, USP15, USP34, CYLD,          
UCHL1 and TRABID                     
ROR (Reactive oxygen species related) pathway USP1, USP7, USP10 and A20 [93-96]
DUBs altering the Cell Cycle progression USP2, USP3, USP7, USP13, USP17L2, USP19, USP28, USP37, USP39, USP44, USP50, CSN5, BAP1, CYLD and  OTUB-6B [12, 97]
Angiogenesis and metastasis related DUBs USP2, USP2a, USP8, USP18, USP19, USP20, USP28, USP33, USP47, Cezanne, ATXN3L, and MCPIP1 [98-106]
DUBs involved in Apoptosis USP2, USP7, USP8, USP9X, USP15, USP16, USP17, USP18, USP19, USP52, A20, ATXN3  CYLD, UCHL1 and MCPIP1 [12,107,108]
DUBs induced upon cytokine secretion USP17, USP17L2 and  TUD-6B  [97]

Kumar et al.Virology Discovery  2013 1:5DOI : 10.7243/2052-6202-1-5